Could This Be Pfizer's Next Blockbuster Vaccine?
Pfizer (NYSE: PFE) was arguably a prolific vaccine maker before last month, when the U.S. Food and Drug Administration gave full approval for those 16 and older to its COVID-19 vaccine, Comirnaty, which it co-developed with BioNTech (NASDAQ: BNTX).
After all, Pfizer owns the Prevnar pneumococcal vaccine franchise, which brought in $2.52 billion in revenue during the first half of this year. Pfizer's tick-borne encephalitis vaccine, known as TicoVac, also secured FDA approval in the U.S. last month, which could multiply its revenue several times over to about $1 billion annually.
But despite its prominence in the space already, Pfizer is shooting for its next blockbuster vaccine. The company is seeking to expand its reach into the respiratory syncytial virus (RSV) vaccine market. Pfizer took a step in the right direction to achieve this goal by announcing that it was starting phase 3 clinical trials for its RSV vaccine candidate, known as RSVpreF, following promising phase 2 results.
Source Fool.com
